Sethu Siva

Biogen (United States)

Papers

1

Total Citations

5

H-Index

1

About

Dr. Sethu Siva is a distinguished bioprocess scientist whose work centers on accelerating the development and manufacturing of monoclonal antibodies (mAbs) for clinical use. Her primary research focuses on leveraging high-throughput technologies and advanced cell culture strategies to dramatically shorten the timeline from candidate selection to first-in-human trials. In her landmark 2015 case study, Dr. Siva demonstrated how integrating high-throughput screening with optimized cell culture processes could compress development timelines, enabling faster material production for early-phase clinical studies. This work, cited 5 times, addresses a critical bottleneck in the life sciences industry: the urgent need to advance novel therapeutics into the clinic more efficiently. Dr. Siva’s contributions have helped reshape industry approaches to bioprocess development, emphasizing speed without compromising quality. Her research is particularly valuable for students and researchers interested in the intersection of bioprocess engineering, high-throughput experimentation, and translational medicine, offering a practical roadmap for overcoming the challenges of bringing life-saving biologics to patients faster.

Research Focus

Key Achievements

1
H-Index
1
Papers
5
Total Citations
5
Avg Citations/Paper
🏆 Most Cited Paper
Leveraging high‐throughput technology to accelerate the time to clinic: A case study of a mAb
5 citations · 2015
📈 Most Prolific Year: 2015 (1 Papers)
🤝 Key Collaborators: 7
🏛 Institutions: Biogen (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago